GLP-1: otro anlisis con datos de pacientes sugiere que muchos no recuperan rpido el peso Un estudio observacional de la firma de anlisis de datos nference, basado en historias clnicas de ms de 135.000 pacientes en centros acadmicos de EE.UU., indica que una mayora de quienes dejan frmacos GLP?1 como semaglutida (Ozempic, Wegovy) o tirzepatida (Mounjaro, Zepbound) mantienen la prdida de peso o incluso siguen adelgazando durante al menos seis meses, lo que contrasta con ensayos clnicos patrocinados por la industria que describen un rpido rebote tras suspender el tratamiento
Key unknowns include long-term cardiovascular effects, bone density changes, and pancreatic safety
This occurs because GLP-1 drugs can interfere with how birth control pills are absorbed
Innovation now aims not only to shed pounds but also to remodel metabolism, targeting fat distribution, cardiometabolic parameters, and long-term sustainability
This principal difference in organisation between hormonal and neuronal signalling has important implications
Reiter RJ, Sharma R, DA Chuffa LG, Zuccari DA, Amaral FG, Cipolla-Neto J (2024) Melatonin-mediated actions and circadian functions that improve implantation, fetal health and pregnancy outcome
